LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer
November 01 2022 - 7:00AM
LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage
immuno-oncology company focused on developing its proprietary
Gammabody™ platform of bispecific gamma delta T cell engagers,
today announced the appointment of Fred M. Powell as Chief
Financial Officer, effective today. Mr. Powell brings over 20 years
of global CFO experience in the biopharmaceutical industry,
including investor relations, administration, operations and
information technology.
“I am pleased to welcome Fred to LAVA’s
executive team. He brings extensive expertise in financial
leadership and is a seasoned executive having served as a CFO for
several publicly traded biopharmaceutical companies that have
positively impacted patients with wide-ranging diseases and medical
conditions around the world,” said Stephen Hurly, president and
chief executive officer of LAVA Therapeutics. “Fred’s deep insights
into the industry will help drive critical growth initiatives and
strategic financial planning at LAVA as we achieve milestones for
our pipeline of bispecific gamma delta T cell engagers.”
“I joined LAVA to work with an emerging leader
with tremendous potential to create transformative therapeutics for
people with cancer. I am impressed by the team’s significant
knowledge and expertise in oncology, antibodies and gamma delta T
cells, and drug development more broadly,” said Mr. Powell. “During
this important stage of LAVA’s clinical execution and growth, I
look forward to contributing to the strong momentum the Company is
building to bring bispecific gamma delta T cell engagers to
patients.”
Most recently, Mr. Powell served as the
executive vice president and chief financial officer of Antares
Pharma, playing a leading strategic role in the successful $1.0
billion acquisition of Antares by Halozyme Therapeutics in May
2022. He was also CFO at Celator Pharmaceuticals (acquired by Jazz
Pharmaceuticals), OraPharma, Inc. (acquired by Valeant
Pharmaceuticals International) and BMP Sunstone Corporation
(acquired by Sanofi-Aventis) and held various positions of
increasing responsibility at KPMG LLP. Mr. Powell is the vice
chairman of the Advisory Board for Penn State Scranton. He holds a
B.S. in accounting from Pennsylvania State University.
About LAVA TherapeuticsLAVA
Therapeutics N.V. is a clinical-stage immuno-oncology company
utilizing its proprietary Gammabody™ platform to develop
a portfolio of bispecific gamma delta T cell engagers for the
potential treatment of solid and hematologic malignancies. The
Company utilizes bispecific antibodies engineered to selectively
kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell
antitumor effector functions upon cross-linking to tumor-associated
antigens. LAVA-051, the Company’s lead candidate for the treatment
of multiple myeloma, chronic lymphocytic leukemia, and acute
myeloid leukemia, is enrolling patients in a Phase 1/2a clinical
study (NCT04887259). A Phase 1/2a clinical study to evaluate
LAVA-1207 in patients with metastatic castration-resistant prostate
cancer (mCRPC) is also enrolling (NCT05369000). For more
information, please visit www.lavatherapeutics.com, and follow
us on LinkedIn, Twitter and YouTube.
CONTACTSInvestor
Relationsir@lavatherapeutics.com
Argot Partners (IR/Media)212-600-1902lava@argotpartners.com
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Apr 2024 to May 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From May 2023 to May 2024